DaxibotulinumtoxinA is a botulinum toxin used to treat glabellar lines and cervical dystonia in adults. DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent.
- Mechanism
- Curator reviewed · 3 references
DaxibotulinumtoxinA blocks neuromuscular transmission at the neuromuscular junction by binding to glycoprotein structures on cholinergic presynaptic nerve terminals, inhibiting the pre-synaptic release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a soluble N-ethylmaleimide-sensitive factor attachment receptor protein. SNAP-25 facilitates the docking and release of synaptic vesicle membrane contents, such as acetylcholine, within nerve endings. Recovery of neurotransmission occurs gradually as the neuromuscular junction recovers from SNAP25 cleavage and as new nerve endings are formed. Inhibition of acetylcholine release is reversible; however, the duration of action of daxibotulinumtoxinA decreases as there is a subsequent reduction in neurotransmitter release at the neuromuscular junction. This leads to decreased muscular contractions near the injection site.
- Primary indication
- DaxibotulinumtoxinA is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.Curator reviewed · 3 structured indications
- Formula / weight
- 150000.0 Da (approximate)
- First approval
- United States, 2009
- Code names
- RT002 · RTI150
- Brand names
Resolves to
What you can answer from here — as of April 10, 2025
Which drugs share a target with DaxibotulinumtoxinA, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account